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http://dx.doi.org/10.1016/j.jmii.2012Background: Postneurosurgical Gram-negative bacillary meningitis (GNBM) or ventriculitis is
a serious issue. Intraventricular (IVT) therapy has been applied; however, its effectiveness
remains controversial, and the adverse drug effects are considerable.
Methods: The demographic data, treatment strategies, and clinical outcomes of patients with
postneurosurgical GNBM or ventriculitis were recorded.
Results: From 2003 to 2011, data on 127 episodes of infection in 109 patients were collected,
and 15 episodes in 14 patients were treated using a sequential combination of intravenous anti-
biotics and IVT therapy; others received intravenous antibiotics alone. The average age of
patients who received a sequential combination with IVT therapy was 48.9 years, and 71.4%
of the patients were men. The regimens used for IVT therapies included gentamicin
(n Z 4), amikacin (n Z 7), and colistin (n Z 4). After meningitis had been diagnosed, the
average period that elapsed before initiation of IVT therapy was 25.4 days, and the average
duration of IVT therapy was 13.3 days. The most frequently isolated pathogen from
cerebrospinal fluid (CSF) was Acinetobacter baumannii, followed by Pseudomonas aeruginosa,
Escherichia coli, Klebsiella pneumoniae, and Serratia marcescens. The cure rate was 73.3%.Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, 2 Yu-Der
uh.org.tw (C.-Y. Chi), u702026@gmail.com (M.-W. Ho).
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Gram-negative postneurosurgical bacillary infection 205Of note, the mean period to sterilize the CSF after appropriate IVT antibiotic treatment was
6.6 days. There were no incidents of seizure or chemical ventriculitis during this IVT therapy.
Conclusion: The findings of this study suggest that IVT antibiotic therapy is a useful option in
the treatment of postneurosurgical GNBM or ventriculitis, especially for those with a treat-
ment-refractory state.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Nosocomial postneurosurgical meningitis is a serious
medical issue, particularly in patients with Gram-negative
bacillary infection.1 There is an increasing incidence of
postneurosurgical meningitis; this has risen from 12% to 27%
of all cases of bacterial meningitis,2 and the overall
mortality for Gram-negative bacillary meningitis (GNBM)
has been reported to be high.1,3 Furthermore, the treat-
ment strategies for GNBM or ventriculitis have become
more complex. Multiple bacteria with reduced sensitivity to
antibiotics have been emerging4,5; moreover, there are
limitations to antimicrobial concentrations at the sites of
infection.6 Thus, a combination of intravenous (IV) and
intraventricular (IVT) antibiotic administration may be one
choice to ensure sterilization of the cerebrospinal fluid
(CSF) while minimizing adverse drug effects.7
The use of IVT antimicrobial agents remains a chal-
lenging intervention due to limited evidence for the effi-
cacy and safety of this treatment. McCracken et al
demonstrated a threefold increased relative risk for
mortality.8 Conversely, some studies have reported an
overall cure rate of 80% with IVT polymyxins9 and 100% for
those with IVT gentamicin.10,11 In terms of the controversial
option of employing IVT therapy for GNBM, there have been
few well-designed studies and clinical trials to verify IVT
therapy among adult populations.
In this study, we report our experience with IVT antibi-
otic therapy in 15 episodes of postneurosurgical GNBM or
ventriculitis, and we also made a comparison of the clinical
and laboratory data and therapeutic results between
patients receiving IVT therapy and those with IV antibiotic
treatment alone.Methods
Patients and setting
From January 2003 to October 2011, we enrolled patients
who experienced complications including GNBM and ven-
triculitis following neurosurgical procedures at the China
Medical University Hospital, a 2000-bed medical center in
Taiwan. Patients were included when all of the following
criteria were met: (1) isolation of Gram-negative bacilli
from the CSF, (2) a CSF neutrophil count of >10 cells/mL,
(3) clinical features of bacterial central nervous system
(CNS) infection (at least one episode of temperature
>37.5C, headache, or neck stiffness), and (4) neurosur-
gery within the preceding 2 months.10 A second episode ofmeningitis was considered a recurrence if it was due to
a organism different from the one causing the initial
episode or if it was due to the same organism occurring
more than 3 weeks after completion of treatment for the
initial episode.12
All patients were treated empirically with IV antibiotics,
and antibiotic treatment was later adjusted according to
the culture report. The CSF analysis and culture were
repeated once or twice every week until the CSF culture
was negative or until the patient was discharged. Revision
or removal of intracranial devices such as external
ventricular drainage, a ventriculoperitoneal shunt, or an
Ommaya reservoir was decided by the doctor in charge.7
For patients with persistent bacterial growth in CSF
cultures or clinical failure, sequential combination with IVT
therapy was undertaken according to procedures outlined
in previous studies7,10,11,15,19 and the practice guidelines of
the Infectious Diseases Society of America.13 All patients
were followed up for more than 3 months after completion
of antimicrobial treatment. Medical charts were thoroughly
reviewed, and any event of IVT therapy-related adverse
drug effects was recorded.
Definitions
Mixed infection was defined as a patient having two or more
bacterial organisms isolated from the initial CSF cultures.14
Co-infection was defined as a patient having GNBM or
ventriculitis with a simultaneous additional infection.
Efficacy was evaluated by both clinical and bacteriologic
responses to therapy. In the treatment period, clinical
failure was considered to be presentation with deterio-
rating clinical and laboratory signs of meningitis during
appropriate antimicrobial therapy. For the clinical
outcome, treatment failure was defined as death due to
meningitis, or relapse.10 Death was considered to be not
due to meningitis if all of the following criteria were met:
(1) resolving inflammatory parameters; (2) resolution of the
clinical signs of meningitis; (3) a serious illness other than
meningitis determined to be a more probable cause
according to the treating physician; (4) completion of the
antibiotic treatment before death; and (5) two negative
CSF culture results (if performed) before death as modified
by the criteria proposed by Durand et al.12 Relapse was
defined as isolation of the same organism from the CSF or
from a CNS lesion within 3 weeks of completing therapy for
the initial episode.12 The criteria for cure proposed by
Briggs et al.3 were modified as follows: resolution of clinical
and laboratory signs of meningitis; negative CSF culture
results (if performed); and no relapse after withdrawal of
206 J.-H. Wang et al.antibiotics. We considered chemical ventriculitis to be
present if the white blood cell count in the CSF rose with
clinical improvement during IVT therapy.15
Appropriate antimicrobial therapy was defined as the
isolated bacteria being susceptible in vitro to the antimi-
crobial agents with an ability to achieve potentially ther-
apeutic levels.16 The period to CSF sterilization was
counted from the day when appropriate IV or IVT antibiotic
treatment was commenced to the day of the first negative
CSF culture report after treatment. The elapsed period was
calculated from the day when bacteria were first isolated in
the CSF specimen to the day when IVT therapy was
initiated.
Microbiology
The CSF specimens were streaked on Trypticase soy agar
containing 5% sheep blood (TSA II), Levine EMB agar, and
chocolate agar (Becton, Dickinson and Company, Le Pont de
Claix, France). The plates were incubated at 35C for
appropriate time periods. Identification of bacteria and
tests for susceptibility to various antimicrobial agents were
performed with either a disk diffusion test according to the
Clinical and Laboratory Standards Institutes or the BD
Phoenix Automated Microbiology System (Becton, Dickinson
and Company, Le Pont de Claix, France).
Results
From January 2003 to October 2011, there were 301
episodes of culture-proven bacterial meningitis at the
China Medical University Hospital. Of these, 249 episodes
occurred in patients involved in 16,725 neurosurgical
procedures. In total, 127 episodes of GNBM or ventriculitis
in 109 patients who fulfilled the criteria were included in
this study. Table 1 summarizes the demographical data,
clinical and laboratory findings, and therapeutic outcomes
for these episodes. Fifteen episodes in 14 patients were
treated using a sequential combination of IV and IVT
therapy, and patients were followed up for more than
3 months. The remaining 112 episodes in 95 patients were
treated using IV antibiotics only.
There was no significant difference in the demographic
data, except length of hospital stay, between the patients
treated with a sequential combination including IVT
therapy and those who received IV antibiotics only. Among
the 15 episodes that were treated using a sequential
combination of IV and IVT antibiotics, the cure rate was
73.3% (11/15). All four nonsurviving patients died within
2 weeks after completion of therapy. Of these, two had
more than two negative CSF culture results before death;
however, the treating physician determined that meningitis
was the only serious illness that could have been a more
probable cause.
The causative organisms isolated from CSF culture are
listed in Table 2, and the antimicrobial resistance of the
pathogens is listed in Table 3. Among the episodes treated
using sequential combination with IVT therapy, two
patients (14.3%) had mixed infections, one showed
methicillin-resistant Staphylococcus aureus, and the other
was haboring Candida tropicalis. In terms of the causativeorganism, six episodes involving carbapenem-resistant
A. baumannii (40.0%) and one episode involving
carbapenem-resistant P. aeruginosa (6.7%) were seen. By
contrast, there were more Enterobacteriaceae organisms,
especially K. pneumoniae, in patients who received IV
antibiotics alone (41.8% versus 26.7%).
Table 4 details the clinic characteristics, microorgan-
isms, antibiotic treatment, and outcome for 15 IVT episodes
in 14 patients with postneurosurgical GNBM or ventriculitis.
The regimens used for IVT therapies were diverse and
included amikacin (nZ 7), gentamicin (nZ 4), and colistin
(n Z 4). All IVT antibiotics were administered once daily
and had in vitro activity against pathogens isolated from
CSF. The daily IVT antibiotic dosage and duration varied.
IVT therapy was added sequentially because of persistent
bacterial growth in the CSF cultures (n Z 13) or as a result
of clinical failure (n Z 2). The elapsed period from when
bacteria were first isolated in the CSF specimens to the
initiation of IVT therapy was 25.4  17.6 (range 5e63) days,
and the average duration of IVT therapy was 13.3  6.7
(range 3e27) days. In this study, no adverse drug effects,
seizures, or chemical ventriculitis were observed during the
IVT therapy. Of the four patients in the IVT therapy group
who died, P. aeruginosa infection was the most common,
accounting for 75% (3/4) of instances. By contrast, the
mortality rate was 42.9% (12/28) for all cases of P. aeru-
ginosa causing CNS infection in this study.Discussion
Mortality and morbidity rates for GNBM or ventriculitis in
postneurosurgical patients remain unfavorably high.1,3 To
optimize antimicrobial concentrations in CSF, IVT therapy
should be considered for patients infected with drug-
resistant microorganisms or with those it is hard to erad-
icated.7,9e11 However, clinicians have previously been wary
of the IVT treatment modality because of concerns about
IVT treatment-related adverse drug effects; careful prep-
aration and delivery are required to avoid contamination.
In addition, the effectiveness of IVT antibiotics in bacterial
meningitis is controversial, and this treatment is often
reserved for either seriously ill or treatment-refractory
patients.
In this study, we analyzed 127 episodes of GNBM or
ventriculitis in 109 patients who received neurosurgical
procedures over an 8-year period. The cure rate for patients
who received a sequential combination with IVT therapy in
our study was similar to those observed in previous studies,
which ranged from 71.4% to 100%.7,10,11,15,19
In the present study, IVT therapy was added sequentially
for patients with persistent bacterial growth in CSF cultures
or who exhibited clinical failure. The findings of this study
suggest that IVT antibiotic use in postneurosurgical GNBM or
ventriculitis treatment may be able to shorten the period to
CSF sterilization, especially in those with a treatment-
refractory state. This is important, because delayed ster-
ilization of the CSF is associated with adverse neurologic
outcomes.20
Conversely, the mean period that elapsed before the
initiation of IVT therapy in our study was much longer than
that in previous studies.10,19 These variations in the time of
Table 1 Demographic and laboratory data for 127 episodes of Gram-negative bacillary meningitis or ventriculitis in 109
postneurosurgical patients
IV antibiotics plus sequential
IVT therapy
IV antibiotics alone p
n Z 14 (%) n Z 95 (%)
Age (mean, y) 48.9  20.5 53.8  20.2 0.408
Male (%) 10 (71.4) 62 (65.3) 0.769
APACHE II scorea 13.3  5.4 13.1  5.8 0.970
Laboratory dataa
WBC (/mL) 14,207.3  4942.9 12,990.7  6337.1 0.500
CRP (mg/dL) 6.4  6.0 10.1  10.4 0.210
ESR (mm/1 h) 42.0  38.8 60.0  39.3 0.221
BUN (mg/dL) 20.5  15.0 19.4  18.3 0.828
Creatinine (mg/dL) 1.2  1.5 0.9  0.7 0.054
CSF RBC (/mL) 10,353.4  30753.0 29,912.6  73730.7 0.308
CSF WBC (/mL) 7205.6  18883.2 6579.0  24254.5 0.931
CSF PMN (%) 70.1  30.2 72.0  29.0 0.757
CSF glucose (mg/dL) 36.4  16.0 52.4  40.2 0.056
CSF protein (mg/dL) 483.3  671.1 377.8  755.0 0.622
CSF lactate (mg/dL) 67.7  30.5 71.3  47.4 0.870
Underlying conditions
DM 2 (14.3) 23 (24.2) 0.516
Liver cirrhosis 0 (0) 6 (6.3) 1.000
ESRD 0 (0) 3 (3.2) 1.000
Cancer 0 (0) 4 (4.2) 1.000
Steroid using 0 (0) 13 (13.7) 0.212
CNS disease
Intracranial tumor 2 (14.3) 3 (3.2) 0.123
Traumatic brain injury 4 (28.6) 27 (28.4) 1.000
Brain infarction 2 (14.3) 6 (6.3) 0.273
ICHb 2 (14.3) 30 (31.6) 0.777
Otherc 4 (28.6) 29 (30.5) 0.870
Mixed infection 2 (14.3) 8 (8.4) 0.614
Bacteremiaa 3 (21.4) 14 (14.7) 0.455
Co-infection 3 (21.4) 29 (30.5) 0.754
Pneumonia 2 (14.3) 15 (15.8) 1.000
UTI 2 (14.3) 16 (16.8) 1.000
Outcomea
Cure 11 (73.3) 74 (66.0) 0.870
Death 4 (26.7) 34 (30.4) 1.000
Relapse 0 (0) 4 (3.6) 1.000
Length of hospital stay (mean, d)a 122.5  43.7 79.1  49.9 0.002
Period to CSF sterilization (mean, d)a 6.6  4.6 12.9  7.6 0.004
a The denominator was set as episodes: n Z 15 for IV antibiotics plus sequential IVT therapy, and n Z 112 for IV antibiotics alone.
b Intracranial hemorrhage related to traumatic brain injury was excluded.
c Hydrocephalus or increased intracranial pressure without the above cause.
BUN Z blood urea nitrogen; CNS Z central nervous system; CRP Z C-reactive protein; CSF Z cerebrospinal fluid; DM Z diabetes
mellitus; ESR Z erythrocyte sedimentation rate; ESRD Z end-stage renal disease; ICH Z intracranial hemorrhage; IV Z intravenous;
IVT Z intraventricular; PMN Z polymorphonuclear neutrophil granulocytes; RBC Z red blood cell; UTI Z urinary tract infection;
WBC Z white blood cell.
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may be related to the variable mortality rate in those
studies.19 For this reason and because of the bacteriological
cure rate for the patients in this study, we suggest that
timely implementation of effective IVT therapy might
increase the clinical cure rate for postneurosurgical GNBM
or ventriculitis.In the past, the major concern related to IVT therapy
with antimicrobials was the possibility of adverse drug
effects such as seizure, chemical ventriculitis, or hearing
loss.21 In the present study, hearing loss was not assessed
because of the variable consciousness of these post-
neurosurgical patients. In previous reports, the incidence of
these adverse effects varied from 13% to 60% for chemical
Table 2 Causative organisms of 127 episodes of Gram-negative bacillary meningitis or ventriculitis in 109 postneurosurgical
patients
IV antibiotics plus sequential
IVT therapy
IV antibiotics alone Total
n Z 15 (%) n Z 112 (%) n Z 127 (%)
Glucose non-fermenting GNB
Acinetobacter spp.a 7 (46.7) 13 (11.6) 20 (15.7)
Pseudomonas spp.b 3 (20.0) 30 (26.8) 33 (26.0)
Stenotrophomonas maltophilia (0.0) 8 (7.1) 8 (6.3)
Otherc 1 (6.7) 7 (6.3) 8 (6.3)
Glucose-fermenting GNB
Enterobacteriaceae 4 (26.7) 48 (42.9) 52 (40.9)
Escherichia colid 2 (13.3) 9 (8.2) 11 (8.7)
Klebsiella pneumoniae 1 (6.7) 17 (14.6) 18 (14.2)
Serratia marcescens 1 (6.7) 5 (4.6) 6 (4.7)
Citrobacter spp. 0 (0.0) 2 (1.8) 2 (1.6)
Enterobacter spp. 0 (0.0) 10 (8.2) 10 (7.1)
Otherf 0 (0.0) 5 (4.6) 5 (3.9)
Oxidase-positive GNBg 0 (0.0) 6 (5.5) 6 (4.7)
a Six CR Acinetobacter baumannii for IV antibiotics plus sequential IVT therapy, and four for IV antibiotics alone.
b One CR Pseudomonas aeruginosa for IV antibiotics plus sequential IVT therapy.
c Including Achromobacter, Chryseobacterium, Delftia, and Sphingobacterium.
d One Escherichia coli ESBL strain for IV antibiotics plus sequential IVT therapy, and four for IV antibiotics alone.
e Five Klebsiella pneumoniae ESBL strain for IV antibiotics alone.
f Including Morganella, Proteus, and Salmonella.
g Including Aeromonas and, Moraxella.
CR Z carbapenem-resistant; ESBL Z extended-spectrum beta-lactamase; GNB Z Gram-negative bacilli; IV Z intravenous;
IVT Z intraventricular.
208 J.-H. Wang et al.ventriculitis, and from 4% to 20% for treatment-associated
seizures.15,19 Several recent reports have suggested that
the intrathecal or IVT administration of agents such as
polymyxin B, colistin, and vancomycin is not associated
with severe or irreversible adverse IVT drug effects.21
Similarly, we report no incidents of seizure or chemical
ventriculitis during IVT therapy. This indicates that IVT
therapy is safe, but further well-designed studies are
required to provide further evidence on this.
Of the causative organisms, the pathogens most
frequently isolated from the CSF cultures in our study were
Pseudomonas species (26.0%). This finding is similar to
those of some studies,2,17,18 whereas other reports haveTable 3 Antimicrobial resistance of causative organisms fro
Gram-negative bacillary meningitis and ventriculitis treated with
Antimicrobial
agent
Acinetobacter
baumannii
Escherichia
coli
Klebsiella
pneumoniae
Ps
ae
n Z 7 (%) n Z 2 (%) n Z 1 (%) n
Ceftazidime 7 (100) 1 (50.0) 0
Cefotaxime 7 (100) 1 (50.0) 0 (0)
Cefepime 7 (100) 1 (50.0) 0 (0) 0
Carbapenem 6 (85.7) 0 (0) 0 (0) 1
Gentamicin 4 (57.1) 0 (0) 0 (0) 0
Amikacin 4 (57.1) 0 (0) 0 (0) 0
Colistin 0 (0) 0 (0)differed.3,16 Furthermore, we found that P. aeruginosa was
the major cause of mortality in patients who received
sequential combination with IVT therapy. Although this
correlation has not been previously reported in adult pop-
ulations, some studies have reported that P. aeruginosa is
a predictor of unfavorable outcomes in neonates and chil-
dren.22,23 For the above condition, we suggest that more
aggressive interventions and earlier IVT therapy application
for P. aeruginosa meningitis should be considered.
There are two limitations to this study. First, we did not
enroll enough patients who had received a sequential
combination of IV and IVT therapy to analyze the efficacy
of IVT for different causative organisms. Second, withm cerebrospinal fluid in 15 episodes of postneurosurgical
sequential intraventricular therapy
eudomonas
ruginosa
Serratia
marcescens
Sphingobacterium
multivorum
Total
Z 3 (%) n Z 1 (%) n Z 1 (%) n Z 15 (%)
(0) 0 (0) 1 (100) 9 (60.0)
0 (0) 8 (53.3)
(0) 0 (0) 1 (100) 9 (60.0)
(33.3) 0 (0) 0 (0) 7 (46.7)
(0) 0 (0) 0 (0) 4 (26.7)
(0) 0 (0) 0 (0) 4 (26.7)
0 (0)
Table 4 Clinical characteristics and microorganisms isolated from cerebrospinal fluid (CSF) and treatment and outcomes for 15 episodes of postneurosurgical Gram-negative
bacillary meningitis and ventriculitis treated with sequential intraventricular therapy (IVT)
Episode Age (y)
/sex
CSF culture Concurrent IV
antibiotics
IVT therapy Medical condition APACHE II
score
Length of
hospital
stay (d)
Outcome
Daily dose IVT
duration (d)
Elapsed
periodb (d)
1a 79/F Acinetobacter
baumannii
Imipenem Amikacin 50 mg 9 32 Brain infarction s/p
Ommaya
6 213 Cured
2 28/M CR Acinetobacter
baumannii
Meropenem Amikacin 30 mg 11 10 ICH s/p EVD 10 139 Cured
3 39/M CR Acinetobacter
baumanniic
Meropenem/colistin Amikacin 10 mg 18 21 Hydrocephalus s/p VP
shunt AIDS
9 136 Cured
4 31/M CR Acinetobacter
baumannii
Imipenem/colistin Colistin 6.4 mg 27 28 TBI/ICH s/p EVD 11 116 Cured
5 70/F CR Acinetobacter
baumannii
Imipenem/sulbactam/
colistin
Colistin 3.2 mg 20 23 Brain infarction s/p VP
shunt
18 98 Death
6 60/M CR Acinetobacter
baumannii
Meropenem/colistin Colistin 16 mg 7 30 ICH s/p VP shunt 16 83 Cured
7 15/M CR Acinetobacter
baumannii
Meropenem/colistin Colistin 2 mg 10 14 Hydrocephalus s/p EVD
Hypertensive
nephrosclerosis
21 98 Cured
8 53/M Escherichia colid Cefepime/ceftazidime Gentamicin 10 mg 3 19 TBI/ICH s/p EVD 14 177 Cured
9a 79/F Escherichia coli
(ESBL)
Imipenem Amikacin 10 mg 3 48 Brain infarction s/p VP
shunt
6 81 Cured
10 57/M Klebsiella
pneumoniae
Ceftriaxone Amikacin 30 mg 17 5 Hydrocephalus s/p EVD 22 128 Cured
DM
11 77/F Pseudomonas
aeruginosa
Ceftazidime Amikacin 10 mg 15 12 Intracranial tumor s/p
VP shunt
19 172 Death
12 48/F Pseudomonas
aeruginosa
Cefepime Amikacin 50 mg 10 13 Communicated
hydrocephalus s/p
Ommaya
7 66 Death
13 25/M CR Pseudomonas
aeruginosa
Ceftazidime
Meropenem
Gentamicin 4 mg 15 55 TBI/ICH s/p craniotomy 9 147 Death
14 68/M Serratia marcescens Ceftazidime/cefepime Gentamicin 8 mg 14 8 ICH s/p EVD 15 59 Cured
15 35/M Sphingobacterium
multivorum
Imipenem/
trimethoprim/
sulfamethoxazole
Gentamicin 8 mg 21 63 TBI/ICH s/p VP shunt 16 124 Cured
a Two separate episodes in one patient.
b Period from when bacteria were first isolated in the CSF specimen to the initiation of IVT therapy.
c Mixed infection with Candida tropicalis.
d Mixed infection with methicillin-resistant Staphylococcus aureus.
AIDS Z acquired immune deficiency syndrome; CR- Z carbapenem-resistant; DM Z diabetes mellitus; ESBL Z extended-spectrum beta-lactamase; EVD Z external ventricular drain;
ICH Z intracranial hemorrhage; IV Z intravenous; s/p Z status post; TBI Z traumatic brain injury; VP shunt Z ventriculoperitoneal shunt.
G
ra
m
-n
e
ga
tive
p
o
stn
e
u
ro
su
rgica
l
b
a
cilla
ry
in
fe
ctio
n
209
210 J.-H. Wang et al.a retrospective study, it is difficult to define the optimal
regimens, dosage, duration, and indications in IVT antimi-
crobial therapy for postneurosurgical patients with GNBM or
ventriculitis. All of these would influence the treatment
response to IVT therapy. For the above reasons and because
of the high mortality rate among those who received IV
antibiotic treatment alone for postneurosurgical GNBM,
further large-scale prospective studies are needed.
In conclusion, this study details the clinical aspects of
postneurosurgical GNBM or ventriculitis and outlines expe-
riences of sequential combination with IVT therapy. The
findings of this study suggest that IVT antibiotic use can be
one of the options for postneurosurgical GNBM or ven-
triculitis treatment, especially for those with a treatment-
refractory state. Further prospective randomized studies
are needed to determine whether this treatment modality
could shorten the time to CSF sterilization, and thus
improve patients’ outcomes.
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